Voglibose 0.2mg Tablet in PCD pharma franchise in Hyderabad

Voglibose 0.2mg Tablet in pharmaceutical manufacturing company in Mumbai

Voglibose 0.2mg Tablet in pharma franchise in Pune

Voglibose 0.2mg Tablet in pharma suppliers in Delhi

Voglibose 0.2mg Tablet in pharma export companies in Kolkata
Voglibose 0.2mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /voglibose-i-point-p-point-0-point-2-tablets

Vogliviga 0.2 Tablet

Composition : Voglibose I.P. 0.2 Tablets

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹89/-

Vogliviga 0.2 Tablet contains Voglibose 0.2mg, an oral alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. It works by delaying the digestion and absorption of carbohydrates in the intestine, thereby preventing a sudden spike in postprandial (after meal) blood sugar levels. Vogliviga 0.2 Tablet is especially useful in patients whose blood glucose levels are not adequately controlled by diet, exercise, or other oral antidiabetics. It complements other antidiabetic therapies by targeting post-meal glucose control without causing hypoglycemia when used alone.

Read More

About the Product

Vogliviga 0.2 Tablet contains Voglibose 0.2mg, an oral alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. It works by delaying the digestion and absorption of carbohydrates in the intestine, thereby preventing a sudden spike in postprandial (after meal) blood sugar levels. Vogliviga 0.2 Tablet is especially useful in patients whose blood glucose levels are not adequately controlled by diet, exercise, or other oral antidiabetics. It complements other antidiabetic therapies by targeting post-meal glucose control without causing hypoglycemia when used alone.

May cause flatulence, abdominal discomfort, bloating, or diarrhea. These side effects are generally mild and subside with continued use. Rarely, serious gastrointestinal disturbances may occur.

Used for the management of postprandial hyperglycemia in patients with type 2 diabetes mellitus, as part of an overall diabetes treatment plan including diet and exercise.

Not recommended for patients with inflammatory bowel disease, intestinal obstruction, or chronic digestive disorders. Regular monitoring of blood glucose is essential. Should be used under medical supervision, particularly in patients with renal or hepatic impairment.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of the reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation